Innovative therapies to treat and cure
hepatitis B virus (HBV) and other viral diseases

The only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in Development

Combining the ASPIN, ATI-2173, with a Nucleoside Analogue (NA), such as Tenofovir (TDF) or Entecavir (ETV), in a one-pill, once-a-day regimen could completely shut down HBV polymerase activity and viral replication, potentially curing HBV infected individuals

ASPIN Mechanism of Action Video

4th generation capsid assembly
modulator (CAM) program in
development

Antios is currently developing CAMs for the treatment of HBV. Early in vivo data point to a differentiated MOA which, unlike most CAMs, may provide for a more targeted, productive clearance of the virus by the immune system. Our 4th generation CAM program, along with ATI-2173, has the potential to contribute to a functional cure for patients with HBV.

View Press Release

ATI-2173
Active Site Polymerase Inhibitor Nucleotide
ATI-2173
HBV
Hepatitis B virus affects 290 million + worldwide
HBV
ATI-2173
Phase 2a combination study underway
ATI-2173

News

June 8, 2022
Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress™ 2022
April 26, 2022
Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus
March 30, 2022
Antios Therapeutics’ ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies
SEE ALL NEWS

EASL presentations:

Pharmacokinetics of ATI-2173, a novel active site polymerase inhibitor nucleoside, in a Phase 1b clinical trial
VIEW
-
Phase 1 Results for ATI-2173, a novel active site polymerase inhibitor nucleotide, in HBV-infected subjects

VIEW

Improving lives through the
treatment of viral diseases